Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing

Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet